| Year |
Citation |
Score |
| 2024 |
Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, et al. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 110121. PMID 38311031 DOI: 10.1016/j.radonc.2024.110121 |
0.393 |
|
| 2024 |
Wisdom AJ, Barker CA, Chang JY, Demaria S, Formenti S, Grassberger C, Gregucci F, Hoppe BS, Kirsch DG, Marciscano AE, Mayadev J, Mouw KW, Palta M, Wu CC, Jabbour SK, et al. The next chapter in immunotherapy and radiation combination therapy - cancer-specific perspectives. International Journal of Radiation Oncology, Biology, Physics. PMID 38184173 DOI: 10.1016/j.ijrobp.2023.12.046 |
0.349 |
|
| 2024 |
Tate MK, Hernandez M, Chang JY, Lin SH, Liao Z, Koshy SM, Skinner HD, Chun SG. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Research. 44: 133-137. PMID 38159979 DOI: 10.21873/anticanres.16795 |
0.369 |
|
| 2023 |
Zhu XR, Li Y, Yang M, Whitaker TJ, Taylor PA, Zhang X, Poenisch F, Sahoo N, Liao Z, Chang JY. Stereotactic body proton therapy for early stage non-small cell lung cancer - Technical challenges and solutions: The MD Anderson experience. Journal of Radiosurgery and Sbrt. 9: 75-82. PMID 38029015 |
0.38 |
|
| 2023 |
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, et al. The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC. Cancer Research Communications. PMID 37728512 DOI: 10.1158/2767-9764.CRC-23-0084 |
0.372 |
|
| 2023 |
Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet (London, England). PMID 37478883 DOI: 10.1016/S0140-6736(23)01384-3 |
0.385 |
|
| 2023 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 340-350. PMID 37015337 DOI: 10.6004/jnccn.2023.0020 |
0.418 |
|
| 2023 |
Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Cancer. PMID 36994945 DOI: 10.1002/cncr.34755 |
0.354 |
|
| 2023 |
De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, ... ... Chang JY, et al. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals Mutations to Be Associated With Longer Overall Survival. Jco Precision Oncology. 7: e2200540. PMID 36716413 DOI: 10.1200/PO.22.00540 |
0.358 |
|
| 2022 |
Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, ... ... Chang JY, et al. International consensus on radiotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research. 11: 1763-1795. PMID 36248338 DOI: 10.21037/tlcr-22-644 |
0.416 |
|
| 2022 |
Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment Related Pulmonary Adverse Events Induced by Chemoradiation and Durvalumab Affect Survival in Locally Advanced Non-Small Cell Lung Cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 36209942 DOI: 10.1016/j.radonc.2022.10.002 |
0.378 |
|
| 2022 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 497-530. PMID 35545176 DOI: 10.6004/jnccn.2022.0025 |
0.42 |
|
| 2022 |
Chang JY, Verma V. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 531-539. PMID 35545175 DOI: 10.6004/jnccn.2021.7117 |
0.357 |
|
| 2022 |
De Leo AN, Dagan R, Amdur RJ, Yeung AR, Li J, Brooks ED, Gilbo P, Gomez D, Chang JY, Ning M. How Three Academic Centers Prescribe SBRT for Primary Lung Cancer. Practical Radiation Oncology. PMID 35219881 DOI: 10.1016/j.prro.2022.02.006 |
0.391 |
|
| 2022 |
Wu Y, Verma V, Liang F, Lin Q, Zhou Z, Wang Z, Wang Y, Wang J, Chang JY. Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis. International Journal of Radiation Oncology, Biology, Physics. PMID 35196537 DOI: 10.1016/j.ijrobp.2022.02.023 |
0.385 |
|
| 2021 |
Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncologica (Stockholm, Sweden). 1-6. PMID 34913815 DOI: 10.1080/0284186X.2021.2012253 |
0.305 |
|
| 2021 |
Chang JY, Verma V, Feng L, Roth JA. SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply. The Lancet. Oncology. 22: e537-e538. PMID 34856147 DOI: 10.1016/S1470-2045(21)00668-9 |
0.339 |
|
| 2021 |
Chuong MD, Hallemeier CL, Li H, Zhu XR, Zhang X, Tryggestad EJ, Yu J, Yang M, Choi JI, Kang M, Liu W, Knopf A, Meijers A, Molitoris JK, Apisarnthanarax S, ... ... Chang JY, et al. Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Frontiers in Oncology. 11: 748331. PMID 34737959 DOI: 10.3389/fonc.2021.748331 |
0.344 |
|
| 2021 |
Amini A, Verma V, Simone CB, Chetty IJ, Chun SG, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Rybkin II, Slotman BJ, Wolf A, ... Chang JY, et al. American Radium Society™ Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 34571054 DOI: 10.1016/j.ijrobp.2021.09.022 |
0.44 |
|
| 2021 |
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. The Lancet. Oncology. PMID 34529930 DOI: 10.1016/S1470-2045(21)00401-0 |
0.328 |
|
| 2021 |
Farooqi A, Ludmir EB, Mitchell KG, Antonoff MB, Tang C, Lee P, Chang J, Elamin Y, Gomez DR, Gandhi SJ. Increased Biologically Effective Dose (BED) To the Primary Tumor is Associated with Improved Survival in Patients with Oligometastatic NSCLC. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34419505 DOI: 10.1016/j.radonc.2021.08.005 |
0.406 |
|
| 2021 |
Iyengar P, Zhang-Velten E, Court L, Westover K, Yan Y, Lin MH, Xiong Z, Patel M, Rivera D, Chang J, Saunders M, Shivnani A, Lee A, Hughes R, Gerber D, et al. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. Jama Oncology. PMID 34383006 DOI: 10.1001/jamaoncol.2021.3186 |
0.412 |
|
| 2021 |
Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clinical and Translational Radiation Oncology. 28: 54-61. PMID 33778173 DOI: 10.1016/j.ctro.2021.02.011 |
0.393 |
|
| 2021 |
Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clinical Lung Cancer. PMID 33707003 DOI: 10.1016/j.cllc.2021.02.002 |
0.429 |
|
| 2021 |
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 254-266. PMID 33668021 DOI: 10.6004/jnccn.2021.0013 |
0.381 |
|
| 2021 |
Verma V, Chang JY. Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era? Translational Lung Cancer Research. 10: 5-8. PMID 33569287 DOI: 10.21037/tlcr-2020-19 |
0.399 |
|
| 2021 |
Yu Y, Xia L, Zhou J, Wang K, Zhang Y, Zhang C, Liu A, Fan Y, Chang J, Wang L, Liu Y, Lu S. 147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients Journal of Thoracic Oncology. 16: S778. DOI: 10.1016/S1556-0864(21)01989-4 |
0.303 |
|
| 2020 |
Vassiliev ON, Peterson CB, Chang JY, Mohan R. Monte Carlo evaluation of target dose coverage in lung stereotactic body radiation therapy with flattening filter-free beams. Journal of Radiotherapy in Practice. 21: 81-87. PMID 35401050 DOI: 10.1017/s1460396920000886 |
0.306 |
|
| 2020 |
Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, et al. Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34756850 DOI: 10.1016/j.jtho.2020.10.013 |
0.409 |
|
| 2020 |
Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, et al. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33198942 DOI: 10.1016/j.jtho.2020.10.013 |
0.301 |
|
| 2020 |
Chun SG, Simone CB, Amini A, Chetty IJ, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society™ Appropriate Use Criteria: Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33166720 DOI: 10.1016/j.jtho.2020.10.020 |
0.417 |
|
| 2020 |
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Respiratory Medicine. PMID 33096027 DOI: 10.1016/S2213-2600(20)30391-X |
0.401 |
|
| 2020 |
Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. Journal For Immunotherapy of Cancer. 8. PMID 33051340 DOI: 10.1136/jitc-2020-001001 |
0.404 |
|
| 2020 |
Higgins KA, Simone CB, Amini A, Chetty IJ, Donington J, Edelman MJ, Chun SG, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society™ , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33011389 DOI: 10.1016/j.jtho.2020.09.013 |
0.442 |
|
| 2020 |
Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, ... ... Chang JY, et al. Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32916308 DOI: 10.1016/j.jtho.2020.08.022 |
0.387 |
|
| 2020 |
Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clinical Lung Cancer. PMID 32727706 DOI: 10.1016/j.cllc.2020.06.018 |
0.369 |
|
| 2020 |
Ai X, Cai Y, Chu Q, Han C, Lu Y, Qin S, Wu L, Xie C, Yuan Z, Zhong W, Zhu X, Chang JY, Zhu Z. [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 23: 532-540. PMID 32517461 DOI: 10.3779/j.issn.1009-3419.2020.102.24 |
0.454 |
|
| 2020 |
Simone CB, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Seminars in Radiation Oncology. 30: 253-261. PMID 32503791 DOI: 10.1016/j.semradonc.2020.02.007 |
0.317 |
|
| 2020 |
Zeng J, Badiyan SN, Garces YI, Wong T, Zhang X, Simone CB, Chang JY, Knopf AC, Mori S, Iwata H, Meijers A, Li H, Bues M, Liu W, Schild SE, et al. Consensus Statement on Proton Therapy in Mesothelioma. Practical Radiation Oncology. PMID 32461036 DOI: 10.1016/J.Prro.2020.05.004 |
0.337 |
|
| 2020 |
Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. Jama Network Open. 3: e203277. PMID 32320035 DOI: 10.1001/jamanetworkopen.2020.3277 |
0.325 |
|
| 2020 |
Wang Z, Chen M, Sun J, Jiang S, Wang L, Wang X, Sahoo N, Gunn GB, Frank SJ, Nguyen QN, Liao Z, Chang JY, Zhu XR, Zhang X. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 146: 200-204. PMID 32220701 DOI: 10.1016/j.radonc.2020.03.003 |
0.41 |
|
| 2020 |
Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902503. PMID 32160096 DOI: 10.1200/Jco.19.02503 |
0.331 |
|
| 2020 |
Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, et al. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head & Neck. PMID 32129548 DOI: 10.1002/Hed.26117 |
0.334 |
|
| 2020 |
Nantavithya C, Gomez DR, Chang JY, Mohamed ASR, Fuller CD, Li H, Brooks ED, Gandhi SJ. An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 145: 209-214. PMID 32062325 DOI: 10.1016/j.radonc.2020.01.002 |
0.348 |
|
| 2020 |
Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early-Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. PMID 32044413 DOI: 10.1016/j.ijrobp.2020.02.001 |
0.377 |
|
| 2020 |
Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. American Journal of Clinical Oncology. PMID 31990759 DOI: 10.1097/Coc.0000000000000632 |
0.329 |
|
| 2020 |
Welsh JW, Chen D, Baas P, Chang JY, Verma V, Comeaux N, Skoulidis F, Lin SH, Heymach J, Theelen W. Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials. Journal of Clinical Oncology. 38: 9548-9548. DOI: 10.1200/jco.2020.38.15_suppl.9548 |
0.3 |
|
| 2020 |
Chang JY, Lin SH, Yao L, Gandhi S, Liao ZX, Chun SG, Jeter M, Welsh JW, Lee P, Antonoff M, Feng L, Lee JJ, Heymach J. I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects. Journal of Clinical Oncology. 38: 9035-9035. DOI: 10.1200/jco.2020.38.15_suppl.9035 |
0.318 |
|
| 2020 |
Simone C, Amini A, Chetty I, Choi JI, Chun S, Donington J, Edelman M, Higgins K, Kestin L, Mohindra P, Movsas B, Rodrigues G, Rosenzweig K, Rybkin I, Shepherd A, ... ... Chang J, et al. American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology*Biology*Physics. 108: E48-E49. DOI: 10.1016/J.Ijrobp.2020.02.583 |
0.303 |
|
| 2020 |
Amini A, Verma V, Simone C, Chetty I, Choi JI, Chun S, Donington J, Edelman M, Higgins K, Kestin L, Mohindra P, Movsas B, Rodrigues G, Rosenzweig K, Rybkin I, ... ... Chang J, et al. American Radium Society® (ARS) Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology*Biology*Physics. 108: E48. DOI: 10.1016/J.Ijrobp.2020.02.582 |
0.422 |
|
| 2020 |
Liu C, Wang J, Chang J, Wu X, Yu H, Sun S, Zhao X, Wang H, Qiao J. 1801P Safety and efficacy of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer Annals of Oncology. 31: S1042. DOI: 10.1016/j.annonc.2020.08.1562 |
0.341 |
|
| 2019 |
Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1464-1472. PMID 31805526 DOI: 10.6004/Jnccn.2019.0059 |
0.361 |
|
| 2019 |
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, et al. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31778797 DOI: 10.1016/J.Jtho.2019.10.024 |
0.395 |
|
| 2019 |
Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31712134 DOI: 10.1016/j.jtho.2019.10.016 |
0.371 |
|
| 2019 |
Brooks ED, Ning MS, Verma V, Zhu XR, Chang JY. Proton therapy for non-small cell lung cancer: the road ahead. Translational Lung Cancer Research. 8: S202-S212. PMID 31673525 DOI: 10.21037/tlcr.2019.07.08 |
0.417 |
|
| 2019 |
Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, et al. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunology Research. PMID 31658994 DOI: 10.1158/2326-6066.Cir-18-0793 |
0.36 |
|
| 2019 |
Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-small Cell Lung Cancer: A Phase II Randomized Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 31627177 DOI: 10.1016/j.ijrobp.2019.10.010 |
0.338 |
|
| 2019 |
Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, et al. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31605794 DOI: 10.1016/j.jtho.2019.10.001 |
0.436 |
|
| 2019 |
Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, Welsh JW, Ye R, Miao H, Chang JY. Predicting 5-Year Progression and Survival Outcomes for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy: Development and Validation of Robust Prognostic Nomograms. International Journal of Radiation Oncology, Biology, Physics. PMID 31586665 DOI: 10.1016/J.Ijrobp.2019.09.037 |
0.362 |
|
| 2019 |
Zhuang H, Shi S, Chang JY. Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Translational Lung Cancer Research. 8: 524-531. PMID 31555525 DOI: 10.21037/tlcr.2019.07.03 |
0.377 |
|
| 2019 |
Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, et al. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. Jama Oncology. PMID 31529018 DOI: 10.1001/jamaoncol.2019.2809 |
0.305 |
|
| 2019 |
Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31479748 DOI: 10.1016/J.Jtho.2019.08.2505 |
0.38 |
|
| 2019 |
Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clinical Lung Cancer. PMID 31078421 DOI: 10.1016/j.cllc.2019.03.001 |
0.407 |
|
| 2019 |
Louie AV, Chang JY. Turning up the stereo in lung cancer Therapeutic Radiology and Oncology. 3: 23-23. DOI: 10.21037/TRO.2019.06.02 |
0.366 |
|
| 2019 |
Welsh JW, Menon H, Tang C, Verma V, Altan M, Hess KR, de Groot P, Nguyen Q, Simon GR, Skoulidis F, Chang JY, Papadimitrakopoulou V, Heymach J. Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer. Journal of Clinical Oncology. 37: 9104-9104. DOI: 10.1200/JCO.2019.37.15_SUPPL.9104 |
0.312 |
|
| 2018 |
Moreno AC, Zhang N, Giordano SH, Liao Z, Gomez D, Chang JY, Lin SH. Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. International Journal of Particle Therapy. 5: 18-27. PMID 31773031 DOI: 10.14338/IJPT/18-00029.1 |
0.433 |
|
| 2018 |
Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, ... ... Chang JY, et al. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. Jama Network Open. 1: e181390. PMID 30646121 DOI: 10.1001/jamanetworkopen.2018.1390 |
0.372 |
|
| 2018 |
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, et al. Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 30513377 DOI: 10.1016/J.Ijrobp.2018.11.051 |
0.39 |
|
| 2018 |
Verma V, Chang JY. Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. Translational Lung Cancer Research. 7: S280-S282. PMID 30393622 DOI: 10.21037/tlcr.2018.04.08 |
0.407 |
|
| 2018 |
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 807-821. PMID 30006423 DOI: 10.6004/Jnccn.2018.0062 |
0.369 |
|
| 2018 |
de Groot PM, Shroff GS, Ahrar J, Sabloff BS, Gladish GM, Moran C, Gupta S, Gladish GW, Chang JY, Erasmus JJ. Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. Advances in Radiation Oncology. 3: 139-145. PMID 29904738 DOI: 10.1016/j.adro.2017.12.005 |
0.343 |
|
| 2018 |
Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Translational Lung Cancer Research. 7: 199-204. PMID 29876319 DOI: 10.21037/tlcr.2018.04.12 |
0.45 |
|
| 2018 |
Verma V, Chang JY. Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. Journal of Thoracic Disease. 10: S1124-S1126. PMID 29849206 DOI: 10.21037/jtd.2018.03.155 |
0.407 |
|
| 2018 |
Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, ... ... Chang JY, et al. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29680255 DOI: 10.1016/j.ijrobp.2018.02.022 |
0.39 |
|
| 2018 |
Verma V, Chang JY. Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. Journal of Thoracic Disease. 10: 21-24. PMID 29600013 DOI: 10.21037/jtd.2017.11.141 |
0.418 |
|
| 2018 |
Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW. Combining radiation plus immunotherapy to improve systemic immune response. Journal of Thoracic Disease. 10: S468-S479. PMID 29593892 DOI: 10.21037/jtd.2018.01.130 |
0.308 |
|
| 2018 |
Liu C, Schild SE, Chang JY, Liao Z, Korte S, Shen J, Ding X, Hu Y, Kang Y, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29550033 DOI: 10.1016/J.Ijrobp.2018.02.009 |
0.325 |
|
| 2018 |
Chang JY, Feng L, Lin SH, Welsh JW, Antonoff M, Gomez DR, Heymach J. Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR. Journal of Clinical Oncology. 36: TPS8580-TPS8580. DOI: 10.1200/JCO.2018.36.15_SUPPL.TPS8580 |
0.392 |
|
| 2018 |
LI H, Verma V, Brooks E, Feng L, Welsh JW, Lin SH, Gomez DR, Gandhi S, Heymach J, Chang JY. Impact of corticosteroid administration on outcomes following stereotactic ablative radiotherapy for non-small cell lung cancer. Journal of Clinical Oncology. 36: e20518-e20518. DOI: 10.1200/jco.2018.36.15_suppl.e20518 |
0.387 |
|
| 2017 |
Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. International Journal of Radiation Oncology, Biology, Physics. 99: 667-676. PMID 29280461 DOI: 10.1016/J.Ijrobp.2017.06.2450 |
0.313 |
|
| 2017 |
Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29246722 DOI: 10.1016/J.Ijrobp.2017.10.046 |
0.363 |
|
| 2017 |
Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 29054376 DOI: 10.1016/J.Radonc.2017.09.018 |
0.44 |
|
| 2017 |
Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of thoracic cancers with intensity modulated proton therapy. Practical Radiation Oncology. PMID 28867546 DOI: 10.1016/j.prro.2017.07.002 |
0.311 |
|
| 2017 |
Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer: Final Results of a Phase 2 Study. Jama Oncology. e172032. PMID 28727865 DOI: 10.1001/Jamaoncol.2017.2032 |
0.402 |
|
| 2017 |
Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, ... Chang JY, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. PMID 28346656 DOI: 10.1002/Cncr.30693 |
0.389 |
|
| 2017 |
Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small-Cell Lung Cancer: A Phase II Clinical Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28259750 DOI: 10.1016/J.Jtho.2017.02.018 |
0.423 |
|
| 2017 |
Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly M, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28139305 DOI: 10.1016/J.Radonc.2016.10.022 |
0.387 |
|
| 2017 |
Brooks E, Sun B, Zhao L, Komaki R, Liao ZX, Jeter M, O'Reilly M, Welsh JW, Gomez DR, Nguyen Q, Antonoff M, Hahn SM, Heymach J, Rice DC, Chang JY. Salvage guideline for local-regional failure after stereotactic ablative radiotherapy for early-stage non-small cell lung cancer. Journal of Clinical Oncology. 35: 8501-8501. DOI: 10.1200/JCO.2017.35.15_suppl.8501 |
0.319 |
|
| 2016 |
Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 28258887 DOI: 10.1016/j.ijrobp.2016.12.022 |
0.363 |
|
| 2016 |
Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Practical Radiation Oncology. PMID 27637136 DOI: 10.1016/j.prro.2016.05.009 |
0.335 |
|
| 2016 |
Selek U, Chang JY. Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. Journal of Thoracic Disease. 8: 1394-1397. PMID 27500390 DOI: 10.21037/jtd.2016.05.16 |
0.354 |
|
| 2016 |
Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 27209498 DOI: 10.1016/j.ijrobp.2016.01.065 |
0.377 |
|
| 2016 |
Moghanaki D, Chang JY. Is surgery still the optimal treatment for stage I non-small cell lung cancer? Translational Lung Cancer Research. 5: 183-9. PMID 27183993 DOI: 10.21037/tlcr.2016.04.05 |
0.37 |
|
| 2016 |
Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 95: 505-16. PMID 27084663 DOI: 10.1016/j.ijrobp.2016.01.036 |
0.394 |
|
| 2016 |
Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu X. Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers. 8. PMID 26901225 DOI: 10.3390/Cancers8020023 |
0.322 |
|
| 2016 |
Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients with Non-Small Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management. PMID 26891607 DOI: 10.1016/J.Jpainsymman.2015.12.316 |
0.41 |
|
| 2016 |
Chang JY, Senan S, Smit EF, Roth JA. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply. The Lancet. Oncology. 17: e42-3. PMID 26868349 DOI: 10.1016/S1470-2045(16)00028-0 |
0.37 |
|
| 2016 |
Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Choy H. Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). International Journal of Radiation Oncology, Biology, Physics. 94: 638. PMID 26867895 DOI: 10.1016/J.Ijrobp.2015.11.031 |
0.407 |
|
| 2015 |
Liu W, Schild SE, Chang JY, Liao Z, Chang YH, Wen Z, Shen J, Stoker JB, Ding X, Hu Y, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, et al. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 26725727 DOI: 10.1016/J.Ijrobp.2015.11.002 |
0.301 |
|
| 2015 |
Chang JY, Senan S, Smit EF, Roth JA. Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply. The Lancet. Oncology. 16: e374-5. PMID 26248841 DOI: 10.1016/S1470-2045(15)00154-0 |
0.349 |
|
| 2015 |
Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Journal of Geriatric Oncology. PMID 26094172 DOI: 10.1016/j.jgo.2015.05.002 |
0.34 |
|
| 2015 |
Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 115: 367-72. PMID 26028228 DOI: 10.1016/J.Radonc.2015.05.014 |
0.411 |
|
| 2015 |
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Oncology. 16: 630-7. PMID 25981812 DOI: 10.1016/S1470-2045(15)70168-3 |
0.361 |
|
| 2015 |
Willers H, Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY. ACR Appropriateness Criteria(®) induction and adjuvant therapy for N2 non-small-cell lung cancer. American Journal of Clinical Oncology. 38: 197-205. PMID 25803563 DOI: 10.1097/Coc.0000000000000154 |
0.36 |
|
| 2015 |
Chang JY. Intensity-modulated radiotherapy, not 3 dimensional conformal, is the preferred technique for treating locally advanced lung cancer. Seminars in Radiation Oncology. 25: 110-6. PMID 25771415 DOI: 10.1016/j.semradonc.2014.11.002 |
0.351 |
|
| 2015 |
Grant JD, Shirvani SM, Tang C, Juloori A, Rebueno NC, Allen PK, Chang JY. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Practical Radiation Oncology. 5: e383-91. PMID 25731965 DOI: 10.1016/j.prro.2015.01.005 |
0.397 |
|
| 2015 |
Li H, Zhang X, Park P, Liu W, Chang J, Liao Z, Frank S, Li Y, Poenisch F, Mohan R, Gillin M, Zhu R. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 114: 367-72. PMID 25708992 DOI: 10.1016/J.Radonc.2015.01.017 |
0.338 |
|
| 2015 |
Chang JY, Bezjak A, Mornex F. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 577-85. PMID 25514807 DOI: 10.1097/JTO.0000000000000453 |
0.356 |
|
| 2015 |
Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clinical Lung Cancer. 16: 156-63. PMID 25467928 DOI: 10.1016/j.cllc.2014.10.005 |
0.452 |
|
| 2015 |
Jiang W, Tang C, Chang JY. Radiation with immunotherapy: an emerging combination for cancer treatment Journal of Radiation Oncology. 4: 331-338. DOI: 10.1007/s13566-015-0217-4 |
0.302 |
|
| 2014 |
Kardar L, Li Y, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Practical Radiation Oncology. 4: e259-68. PMID 25407877 DOI: 10.1016/J.Prro.2014.06.010 |
0.352 |
|
| 2014 |
Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. Jama Surgery. 149: 1244-53. PMID 25321323 DOI: 10.1001/jamasurg.2014.556 |
0.4 |
|
| 2014 |
McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. International Journal of Radiation Oncology, Biology, Physics. 90: 819-27. PMID 25220718 DOI: 10.1016/J.Ijrobp.2014.07.030 |
0.395 |
|
| 2014 |
Videtic GM, Chang JY, Chetty IJ, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Loo BW, Movsas B, Stinchcombe TE, Willers H, Rosenzweig KE. ACR appropriateness Criteria® early-stage non-small-cell lung cancer. American Journal of Clinical Oncology. 37: 201-7. PMID 25180631 DOI: 10.1097/Coc.0000000000000013 |
0.38 |
|
| 2014 |
Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Videtic GM, Willers H. ACR Appropriateness Criteria® nonsurgical treatment for locally advanced non-small-cell lung cancer: good performance status/definitive intent. Oncology (Williston Park, N.Y.). 28: 706-10, 712, 714 pas. PMID 25140629 |
0.431 |
|
| 2014 |
Grant JD, Chang JY. Proton-based stereotactic ablative radiotherapy in early-stage non-small-cell lung cancer. Biomed Research International. 2014: 389048. PMID 25136582 DOI: 10.1155/2014/389048 |
0.431 |
|
| 2014 |
Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 112: 256-61. PMID 25108807 DOI: 10.1016/j.radonc.2014.07.010 |
0.412 |
|
| 2014 |
Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clinical Pharmacology and Therapeutics. 96: 609-15. PMID 25054431 DOI: 10.1038/Clpt.2014.154 |
0.372 |
|
| 2014 |
Zhu Z, Liu W, Gillin M, Gomez DR, Komaki R, Cox JD, Mohan R, Chang JY. Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiation Oncology (London, England). 9: 108. PMID 24886059 DOI: 10.1186/1748-717X-9-108 |
0.387 |
|
| 2014 |
Zhuang H, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 882-5. PMID 24828665 DOI: 10.1097/JTO.0000000000000126 |
0.445 |
|
| 2014 |
Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. Journal of Thoracic Disease. 6: 348-55. PMID 24688779 DOI: 10.3978/j.issn.2072-1439.2013.11.07 |
0.437 |
|
| 2014 |
Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. Journal of Thoracic Disease. 6: 285-6. PMID 24688773 DOI: 10.3978/j.issn.2072-1439.2013.12.47 |
0.399 |
|
| 2014 |
Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". International Journal of Radiation Oncology, Biology, Physics. 88: 1120-8. PMID 24661665 DOI: 10.1016/j.ijrobp.2014.01.022 |
0.444 |
|
| 2014 |
Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Research. 74: 2476-86. PMID 24618342 DOI: 10.1158/0008-5472.Can-13-2968 |
0.311 |
|
| 2014 |
Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Medical Physics. 41: 021721. PMID 24506612 DOI: 10.1118/1.4862076 |
0.351 |
|
| 2014 |
Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher S, Smith BD. Lobectomy, sublobar resection, and stereotactic radiation for early-stage non-small cell lung cancers in the elderly. Journal of Clinical Oncology. 32: 7555-7555. DOI: 10.1200/jco.2014.32.15_suppl.7555 |
0.413 |
|
| 2014 |
Skinner HD, Komaki RU, Chang JY, Cox JD. Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-Small Cell Lung Cancer Lung Cancer: Fourth Edition. 379-389. DOI: 10.1002/9781118468791.ch24 |
0.404 |
|
| 2014 |
Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH. Lung Cancer: Fourth Edition Lung Cancer: Fourth Edition. 1-602. DOI: 10.1002/9781118468791 |
0.364 |
|
| 2013 |
Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1484-91. PMID 24389430 DOI: 10.1097/JTO.0b013e3182a5fdcb |
0.326 |
|
| 2013 |
Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists. 38: 442-7. PMID 24200220 DOI: 10.1016/J.Meddos.2013.08.001 |
0.403 |
|
| 2013 |
Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer (Amsterdam, Netherlands). 82: 252-9. PMID 24018022 DOI: 10.1016/j.lungcan.2013.08.015 |
0.37 |
|
| 2013 |
McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 109: 38-44. PMID 24016675 DOI: 10.1016/J.Radonc.2013.08.014 |
0.385 |
|
| 2013 |
Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thoracic Surgery Clinics. 23: 369-81. PMID 23931020 DOI: 10.1016/j.thorsurg.2013.05.009 |
0.373 |
|
| 2013 |
Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 87: 139-47. PMID 23920393 DOI: 10.1016/J.Ijrobp.2013.05.040 |
0.409 |
|
| 2013 |
Chang JY. Oncology scan--promising strategies for the treatment of locally-advanced non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 87: 1-4. PMID 23920382 DOI: 10.1016/J.IJROBP.2013.04.013 |
0.399 |
|
| 2013 |
Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. Journal of the American College of Radiology : Jacr. 10: 654-64. PMID 23890874 DOI: 10.1016/J.Jacr.2013.05.031 |
0.438 |
|
| 2013 |
Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 119: 3402-10. PMID 23798353 DOI: 10.1002/cncr.28217 |
0.384 |
|
| 2013 |
Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 86: 665-70. PMID 23688815 DOI: 10.1016/J.Ijrobp.2013.03.035 |
0.465 |
|
| 2013 |
Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer. American Journal of Clinical Oncology. 36: 206-13. PMID 23511336 DOI: 10.1097/Coc.0B013E31827E5523 |
0.37 |
|
| 2013 |
Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H. Oligometastases/Oligo-recurrence of lung cancer. Pulmonary Medicine. 2013: 438236. PMID 23476762 DOI: 10.1155/2013/438236 |
0.378 |
|
| 2013 |
Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 895-902. PMID 23341526 DOI: 10.1200/JCO.2011.40.1174 |
0.372 |
|
| 2013 |
Selek U, Chang JY. Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer Lung Cancer Management. 2: 213-225. DOI: 10.2217/LMT.13.14 |
0.421 |
|
| 2013 |
Skinner HD, Pu X, Chang J, Lu C, Komaki R, Wu X. Abstract 77: Genetic variations in the stem cell pathway predict for toxicity following radiotherapy in lung cancer. Cancer Research. 73: 77-77. DOI: 10.1158/1538-7445.Am2013-77 |
0.392 |
|
| 2013 |
Pu X, Skinner HD, Ye Y, Hildebrandt MA, Chang JY, Lu C, Komaki R, Minna JD, Roth JA, Wu X. Abstract 4582: Genome-wide association study of toxicity following definitive radiotherapy in non-small cell lung cancer patients. Epidemiology. 73: 4582-4582. DOI: 10.1158/1538-7445.Am2013-4582 |
0.371 |
|
| 2013 |
Pu X, Wang L, Hildebrandt MA, Ye Y, Chang JY, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Abstract 3626: Inflammation-related genetic variants predict radiation-induced toxicity following definitive radiotherapy for non-small cell lung cancer. Cancer Research. 73: 3626-3626. DOI: 10.1158/1538-7445.Am2013-3626 |
0.329 |
|
| 2013 |
Shu X, Lu C, Chang JY, Roth JA, Wu X. Abstract 1350: Genetic variations in apoptosis pathway are associated with survival in late stage non-small cell lung cancer. Cancer Research. 73: 1350-1350. DOI: 10.1158/1538-7445.Am2013-1350 |
0.339 |
|
| 2012 |
Shirvani SM, Chang JY. Proton therapy for non-small cell lung cancer: Current evidence and future directions. Thoracic Cancer. 3: 99-108. PMID 28920298 DOI: 10.1111/j.1759-7714.2011.00095.x |
0.463 |
|
| 2012 |
Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. International Journal of Radiation Oncology, Biology, Physics. 84: 1060-70. PMID 22975611 DOI: 10.1016/j.ijrobp.2012.07.2354 |
0.428 |
|
| 2012 |
Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiation Oncology (London, England). 7: 152. PMID 22963661 DOI: 10.1186/1748-717X-7-152 |
0.404 |
|
| 2012 |
Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiation Oncology (London, England). 7: 144. PMID 22929048 DOI: 10.1186/1748-717X-7-144 |
0.319 |
|
| 2012 |
Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? International Journal of Radiation Oncology, Biology, Physics. 84: e69-76. PMID 22901421 DOI: 10.1016/j.ijrobp.2012.02.017 |
0.364 |
|
| 2012 |
Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulmonary Medicine. 2012: 396592. PMID 22900169 DOI: 10.1155/2012/396592 |
0.403 |
|
| 2012 |
Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. The Annals of Thoracic Surgery. 94: 914-20. PMID 22819472 DOI: 10.1016/j.athoracsur.2012.04.088 |
0.365 |
|
| 2012 |
Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 83: 1558-65. PMID 22572078 DOI: 10.1016/J.Ijrobp.2011.10.035 |
0.327 |
|
| 2012 |
Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 84: 1093-100. PMID 22543217 DOI: 10.1016/J.Ijrobp.2012.02.041 |
0.447 |
|
| 2012 |
Liu H, Chang JY. Proton therapy in clinical practice. Chinese Journal of Cancer. 30: 315-26. PMID 21527064 DOI: 10.5732/cjc.010.10529 |
0.305 |
|
| 2012 |
Shirvani SM, Jiang J, Chang JY, Gomez DR, Welsh J, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer in the elderly. Journal of Clinical Oncology. 30: 7062-7062. DOI: 10.1200/jco.2012.30.15_suppl.7062 |
0.395 |
|
| 2011 |
Chang JY, Komaki R, Lu C, When HY, Allen P, Tsao AS, Gillin M, Mohan R, Cox JD. Phase II study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7017. PMID 28020081 DOI: 10.1200/jco.2011.29.15_suppl.7017 |
0.425 |
|
| 2011 |
Shirvani SM, Chang JY. Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers. 3: 3432-48. PMID 24212962 DOI: 10.3390/cancers3033432 |
0.413 |
|
| 2011 |
Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 1: 52. PMID 22649768 DOI: 10.3389/Fonc.2011.00052 |
0.439 |
|
| 2011 |
Decker RH, Langer CJ, Rosenzweig KE, Chang JY, Gewanter RM, Ginsburg ME, Kong FM, Lally BE, Videtic GM, Movsas B. ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer. American Journal of Clinical Oncology. 34: 537-44. PMID 21946673 DOI: 10.1097/Coc.0B013E318216E5A2 |
0.446 |
|
| 2011 |
Nguyen GH, Murph MM, Chang JY. Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. Cancers. 3: 1232-52. PMID 21603589 DOI: 10.3390/cancers3011232 |
0.383 |
|
| 2011 |
Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 82: e91-7. PMID 21489716 DOI: 10.1016/j.ijrobp.2010.12.072 |
0.388 |
|
| 2011 |
Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, ... ... Chang JY, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. Journal of the National Cancer Institute. 103: 817-25. PMID 21483023 DOI: 10.1093/Jnci/Djr075 |
0.395 |
|
| 2011 |
Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 117: 4707-13. PMID 21437893 DOI: 10.1002/cncr.26080 |
0.408 |
|
| 2011 |
Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 117: 3004-13. PMID 21264827 DOI: 10.1002/Cncr.25848 |
0.417 |
|
| 2011 |
Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 80: 1350-7. PMID 21251767 DOI: 10.1016/J.Ijrobp.2010.04.049 |
0.39 |
|
| 2011 |
Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. International Journal of Radiation Oncology, Biology, Physics. 79: 473-80. PMID 20399032 DOI: 10.1016/J.Ijrobp.2009.11.009 |
0.328 |
|
| 2011 |
Quan E, Chang J, Liao Z, Xia T, Liu H, Li X, Balter P, Zhang X. SU-E-T-784: Automated VMAT Treatment Planning for Stage III Lung Cancer: How Does It Compare with IMRT? Medical Physics. 38: 3671-3671. DOI: 10.1118/1.3612748 |
0.328 |
|
| 2010 |
Gomez DR, Chang JY. Adaptive radiation for lung cancer. Journal of Oncology. 2011. PMID 20814539 DOI: 10.1155/2011/898391 |
0.372 |
|
| 2010 |
Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. International Journal of Radiation Oncology, Biology, Physics. 78: 969-74. PMID 20813465 DOI: 10.1016/J.Ijrobp.2010.07.028 |
0.369 |
|
| 2010 |
Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Seminars in Radiation Oncology. 20: 171-7. PMID 20652085 DOI: 10.1016/J.Semradonc.2010.01.005 |
0.373 |
|
| 2010 |
Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 80: 1015-22. PMID 20615629 DOI: 10.1016/j.ijrobp.2010.03.012 |
0.431 |
|
| 2010 |
Gewanter RM, Rosenzweig KE, Chang JY, Decker R, Dubey S, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Current Problems in Cancer. 34: 228-49. PMID 20541060 DOI: 10.1016/j.currproblcancer.2010.04.001 |
0.409 |
|
| 2010 |
Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. International Journal of Radiation Oncology, Biology, Physics. 78: 1387-93. PMID 20381271 DOI: 10.1016/J.Ijrobp.2009.09.070 |
0.402 |
|
| 2010 |
Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. International Journal of Radiation Oncology, Biology, Physics. 77: 357-66. PMID 19660879 DOI: 10.1016/J.Ijrobp.2009.04.028 |
0.376 |
|
| 2010 |
Chang JY, Komaki R. Proton Therapy in Lung Cancer and Other Thoracic Tumors Radiation Medicine Rounds. 1: 523-537. DOI: 10.5003/2151-4208.1.3.523 |
0.381 |
|
| 2010 |
Pu X, Lippman SM, Gu J, Xing J, Chang J, Chang D, Spitz MR, Wu X. Abstract 879: Mitochondrial DNA content and its association with lung cancer risk and clinical outcomes Cancer Research. 70: 879-879. DOI: 10.1158/1538-7445.Am10-879 |
0.363 |
|
| 2010 |
Pan X, Zhang X, Li Y, Li X, Chang J, Zhu X, Mohan R. MO-D-BRB-09: Inverse Beam Angle Optimization in IMRT for Lung Cancer Patients Medical Physics. 37: 3341-3341. DOI: 10.1118/1.3469061 |
0.303 |
|
| 2009 |
McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer. 115: 3233-42. PMID 19472405 DOI: 10.1002/Cncr.24361 |
0.4 |
|
| 2009 |
Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiation Oncology (London, England). 4: 5. PMID 19183471 DOI: 10.1186/1748-717X-4-5 |
0.346 |
|
| 2009 |
Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 179-84. PMID 19179893 DOI: 10.1097/JTO.0b013e3181990c46 |
0.367 |
|
| 2009 |
Ezhil M, Vedam S, Balter P, Choi B, Mirkovic D, Starkschall G, Chang JY. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography Radiation Oncology. 4. PMID 19173738 DOI: 10.1186/1748-717X-4-4 |
0.347 |
|
| 2009 |
Britton KR, Starkschall G, Liu H, Chang JY, Bilton S, Ezhil M, John-Baptiste S, Kantor M, Cox JD, Komaki R, Mohan R. Consequences of Anatomic Changes and Respiratory Motion on Radiation Dose Distributions in Conformal Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 73: 94-102. PMID 18929448 DOI: 10.1016/J.Ijrobp.2008.04.016 |
0.302 |
|
| 2008 |
Komaki R, Allen PK, Wei X, Liao Z, Chang JY, Thames H, Glisson BS, Fossella FV, Oh Y, Ohnishi K, Cox JD. Prognostic factors identified in the long term survivors with limited small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7552. PMID 27947367 DOI: 10.1200/Jco.2008.26.15_Suppl.7552 |
0.37 |
|
| 2008 |
Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 72: 967-71. PMID 18954709 DOI: 10.1016/J.Ijrobp.2008.08.001 |
0.442 |
|
| 2008 |
Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics. 18: 955-65. PMID 18854777 DOI: 10.1097/Fpc.0B013E32830Efdd4 |
0.31 |
|
| 2008 |
Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 858-64. PMID 18670303 DOI: 10.1097/Jto.0B013E31818020D5 |
0.365 |
|
| 2008 |
Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, Cox JD, Chang JY. Effects of Interfractional Motion and Anatomic Changes on Proton Therapy Dose Distribution in Lung Cancer International Journal of Radiation Oncology Biology Physics. 72: 1385-1395. PMID 18486357 DOI: 10.1016/J.Ijrobp.2008.03.007 |
0.376 |
|
| 2008 |
Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer Journal of Thoracic Oncology. 3: 177-186. PMID 18303441 DOI: 10.1097/Jto.0B013E3181622Bdd |
0.391 |
|
| 2008 |
Ikushima H, Balter P, Chang J, Hunjan S, Sadagopan R, Yu Z, Zhang Y, Dong L. TU-C-351-05: Daily Alignment Results for In-Room CT-Guided Stereotactic Body Radiation Therapy for Lung Cancer Medical Physics. 35: 2892-2892. DOI: 10.1118/1.2962468 |
0.367 |
|
| 2007 |
Chang JY, Roth JA. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thoracic Surgery Clinics. 17: 251-9. PMID 17626403 DOI: 10.1016/j.thorsurg.2007.03.011 |
0.355 |
|
| 2007 |
Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 68: 1349-58. PMID 17446001 DOI: 10.1016/J.Ijrobp.2007.02.015 |
0.374 |
|
| 2007 |
Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. International Journal of Radiation Oncology, Biology, Physics. 68: 779-85. PMID 17418967 DOI: 10.1016/J.Ijrobp.2007.01.002 |
0.344 |
|
| 2007 |
Liu H, Wang X, Hu C, Yom S, Wang S, Tucker S, Liao Z, Chang J, Komaki R, Mohan R. WE-C-M100F-05: Methodology and Guidelines in Treatment Planning of IMRT for Lung Cancers Medical Physics. 34: 2592-2592. DOI: 10.1118/1.2761524 |
0.336 |
|
| 2007 |
Chang JY, Balter P, Liao Z, Bucci KM, McAleer MF, Yang Q, Dong L, Roth JA, Cox JD, Komaki R. PD5-2-6: Hypofractionated stereotactic body radiotherapy in patients with peripherally or centrally located medically inoperable stage I or isolated recurrent non-small cell lung cancer Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283432.89638.84 |
0.336 |
|
| 2007 |
Kang Y, Bucci MK, Liao Z, Liu HH, Tucker SL, Chang JY, Komaki R, Cox JD, Mohan R, Dong L. PD5-1-8: 4D CT imaging impacts lung volume definitions and dose-volume relationships in radiation treatment of non-small cell lung cancer Journal of Thoracic Oncology. 2: S474. DOI: 10.1097/01.JTO.0000283426.82014.6F |
0.374 |
|
| 2007 |
Cox JD, Chang J, Liao Z, Bucci MK, McAleer MF, Wei X, Allen PK, Cai H, Gillin MT, Zhu R, Sahoo N, Woo SY, Komaki R. PD4-1-6: Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLS): Reduction in incidence and severity despite higher doses Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283376.48091.90 |
0.344 |
|
| 2007 |
Chang JY, Zhang X, Cox JD. Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer: In Reply to Dr. Armstrong International Journal of Radiation Oncology Biology Physics. 68: 1272. DOI: 10.1016/J.Ijrobp.2007.02.038 |
0.369 |
|
| 2006 |
Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 526-31. PMID 17409912 DOI: 10.1016/S1556-0864(15)30354-3 |
0.313 |
|
| 2006 |
Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4485-91. PMID 16983118 DOI: 10.1200/JCO.2006.07.1126 |
0.348 |
|
| 2006 |
Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, et al. Non-small cell lung cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 4: 548-82. PMID 16813724 |
0.356 |
|
| 2006 |
Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 66: 117-25. PMID 16765528 DOI: 10.1016/j.ijrobp.2006.04.013 |
0.44 |
|
| 2006 |
Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume International Journal of Radiation Oncology Biology Physics. 65: 573-586. PMID 16690439 DOI: 10.1016/j.ijrobp.2006.01.032 |
0.348 |
|
| 2006 |
Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non–small-cell lung cancer International Journal of Radiation Oncology Biology Physics. 65: 1087-1096. PMID 16682145 DOI: 10.1016/J.Ijrobp.2006.01.052 |
0.36 |
|
| 2005 |
Komaki R, Allen P, Glisson B, Lu C, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with Concurrent Chemotherapy (ChT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7158. PMID 27944978 DOI: 10.1200/Jco.2005.23.16_Suppl.7158 |
0.397 |
|
| 2005 |
Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 77: 247-53. PMID 16298001 DOI: 10.1016/j.radonc.2005.10.017 |
0.389 |
|
| 2005 |
Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6657-68. PMID 16166445 DOI: 10.1158/1078-0432.CCR-04-2699 |
0.341 |
|
| 2005 |
Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Current Oncology Reports. 7: 255-9. PMID 15946583 DOI: 10.1007/S11912-005-0047-4 |
0.462 |
|
| 2005 |
Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3342-8. PMID 15867233 DOI: 10.1158/1078-0432.Ccr-04-1741 |
0.337 |
|
| 2005 |
Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2894-8. PMID 15837739 DOI: 10.1158/1078-0432.Ccr-04-2176 |
0.341 |
|
| 2005 |
Liu H, Wang X, Murshed H, Stevens C, Guerrero T, Balter PA, Prado K, Liao Z, Chang JY, Komaki R, Cox J, Mohan R. TU-E-T-6C-02: Clinical Implementation of IMRT for Lung Cancers Medical Physics. 32: 2102-2103. DOI: 10.1118/1.1999715 |
0.411 |
|
| 2005 |
Liao Z, Komaki R, Milas L, Chen Y, Kies M, Chang J, Jeter M, Guerrero T, Blumenschein G, Cox J. P-959 A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC) Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)81452-7 |
0.418 |
|
| 2005 |
Chang J, Dong L, Mohan R, Liao Z, Cox J, Komaki R. PD-088 Image-guided proton radiotherapy for medically inoperable stage I non-small cell lung cancer Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80421-0 |
0.321 |
|
| 2005 |
Yom S, Liao Z, Liu H, Allen P, Chang J, Jeter M, Guerrero T, Stevens C, Cox J, Komaki R. O-152 Analysis of acute toxicity results of intensity modulated radiationtherapy (IMRT) in the treatment of non-small cell lung cancer (NSCLC) Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80286-7 |
0.356 |
|
| 2004 |
Komaki R, Spitz MR, Wu X, Chang JY, Allen PK, Lika M, Fossella FV, Stevens CW, Liao Z, Cox JD. Mutagen Sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7232. PMID 28013872 DOI: 10.1200/Jco.2004.22.14_Suppl.7232 |
0.392 |
|
| 2004 |
Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R, Change JY. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 58: 1258-67. PMID 15001271 DOI: 10.1016/J.Ijrobp.2003.09.086 |
0.387 |
|
| 1998 |
Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model Gene Therapy. 5: 1538-1544. PMID 9930307 DOI: 10.1038/Sj.Gt.3300771 |
0.333 |
|
| Show low-probability matches. |
